A Phase 1 study of DV281 for treatment of lung cancer.
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2017
At a glance
- Drugs DV 281 (Primary)
- Indications Lung cancer
- Focus Adverse reactions
- 12 Jan 2017 New trial record
- 05 Jan 2017 According to a Dynavax Technologies media release, company anticipates initiating this trial in the second quarter of 2017.